ArticleNature2026
mRNA vaccines engage unconventional pathways in CD8
Abstract read
In one paragraph
Article in Nature, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Novel lipid nanoparticle in a mRNA cancer vaccine drives tumor control via type I IFNs and effector CD8Molecular therapy. Nucleic acids · 2026Article
- Bioengineering strategies for improving the immunogenicity of mRNA vaccines.Signal transduction and targeted therapy · 2026Review
- Spatiotemporal control of STING activation and saRNA delivery decouples humoral and cellular immunity.bioRxiv : the preprint server for biology · 2026Article
- Developing neoantigen cancer vaccines: where are we now?Nature communications · 2026Review
- Synthetic long peptide and DNA personalized cancer vaccines induce robust neoantigen-specific T cell responses in pancreatic cancer.Science advances · 2026Article
- mRNA Therapeutics Beyond Infectious Diseases: Expanding Therapeutic Applications and Future Perspectives.Immunity, inflammation and disease · 2026Review
- Development of Autologous Dendritic Cell Vaccine Therapeutics for Canine Mammary Cancer.Genes · 2026Review
- Revealing the pathogenesis of autoimmune hepatitis and research progress in drug discovery from hepatic immune cells and intercellular communication signaling mechanisms.Frontiers in immunology · 2026Review
- mRNA processing in cancer immunotherapy: emerging targets, resistance mechanisms, and therapeutic opportunities.Frontiers in immunology · 2026Review
- Targeting innate immunity in cancer: mechanistic foundations, therapeutic vaccination, and clinical translation.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Suin JoDepartment of Pathology and Immunology, Washington University in St Louis School of Medicine, St Louis, MO, USA.ORCID http://orcid.org/0000-0002-7575-9017
Lijin LiDepartment of Surgery, Washington University in St Louis School of Medicine, St Louis, MO, USA.ORCID http://orcid.org/0000-0001-6203-8854
Chandrani ThakurDepartment of Neurology, Washington University School of Medicine, St Louis, MO, USA.ORCID http://orcid.org/0000-0003-2833-0610
Kevin A TelferDepartment of Pathology and Immunology, Washington University in St Louis School of Medicine, St Louis, MO, USA.
Hussein SultanDepartment of Pathology and Immunology, Washington University in St Louis School of Medicine, St Louis, MO, USA.ORCID http://orcid.org/0000-0003-4067-8169
Ray A OharaDepartment of Pathology and Immunology, Washington University in St Louis School of Medicine, St Louis, MO, USA.ORCID http://orcid.org/0000-0001-7897-3169
Michelle HeDepartment of Pathology and Immunology, Washington University in St Louis School of Medicine, St Louis, MO, USA.ORCID http://orcid.org/0009-0004-1579-5595
Giri NamDepartment of Pathology and Immunology, Washington University in St Louis School of Medicine, St Louis, MO, USA.
Jing ChenDepartment of Pathology and Immunology, Washington University in St Louis School of Medicine, St Louis, MO, USA.
Feiya OuDepartment of Pathology and Immunology, Washington University in St Louis School of Medicine, St Louis, MO, USA.ORCID http://orcid.org/0000-0001-8289-4025
Monia DraghiInnovac Therapeutics, Cambridge, MA, USA.
Nicholas M ValianteInnovac Therapeutics, Cambridge, MA, USA.
Robert D SchreiberDepartment of Pathology and Immunology, Washington University in St Louis School of Medicine, St Louis, MO, USA.ORCID http://orcid.org/0000-0003-1590-2341
Gwendalyn J RandolphDepartment of Pathology and Immunology, Washington University in St Louis School of Medicine, St Louis, MO, USA.ORCID http://orcid.org/0000-0001-9045-1195
Naresha SaligramaDepartment of Pathology and Immunology, Washington University in St Louis School of Medicine, St Louis, MO, USA.ORCID http://orcid.org/0000-0003-2526-7150
Theresa L MurphyDepartment of Pathology and Immunology, Washington University in St Louis School of Medicine, St Louis, MO, USA.
William E GillandersDepartment of Surgery, Washington University in St Louis School of Medicine, St Louis, MO, USA. gillandersw@wustl.edu.ORCID http://orcid.org/0000-0002-0465-3071
Kenneth M MurphyDepartment of Pathology and Immunology, Washington University in St Louis School of Medicine, St Louis, MO, USA. kmurphy@wustl.edu.ORCID http://orcid.org/0000-0002-3505-9630
Funding
Washington University Center for Cellular ImagingP30CA091842 · NCI · WASHINGTON UNIVERSITY · PI TIMOTHY J. EBERLEIN · 2001 to 2026
$128.0MWashington University SPORE in Pancreatic CancerP50CA196510 · NCI · WASHINGTON UNIVERSITY · PI HAWKINS, WILLIAM G · 2016 to 2020
$10.9McGMP Manufacture, Fill-Finish, Release, Analytical and Stability Testing and Stability Program of a Nanoparticle Based HIV Envelope Vaccine75N93022D00005 · NIAID · INTERNATIONAL AIDS VACCINE INITIATIVE · PI HASSELL, THOMAS · 2022 to 2025
$8.0MTask Area A shall encompass annual follow-up of cohort members, clinical events investigations, study operations, and data analysis and manuscript writing. If implemented, Task A.1 will provide fundin75N92020D00005 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI WATSON, KAROL E · 2020 to 2025
$5.1MTargeting Neoantigens in Triple Negative Breast CancerR01CA240983 · NCI · WASHINGTON UNIVERSITY · PI GILLANDERS, WILLIAM E., SCHREIBER, ROBERT DAVID · 2019 to 2023
$3.2MMolecular Basis of cDC1 DevelopmentR01AI162643 · NIAID · WASHINGTON UNIVERSITY · PI MURPHY, KENNETH M · 2022 to 2025
$2.8MFunction of Wdfy4 in cross-presentation and immunityR01AI150297 · NIAID · WASHINGTON UNIVERSITY · PI MURPHY, KENNETH M · 2019 to 2023
$2.5MUnderstanding the Mechanisms of DC Licensing in CD8 T Cell PrimingR01CA248919 · NCI · WASHINGTON UNIVERSITY · PI MURPHY, KENNETH M · 2021 to 2025
$2.3MRole of WDFY4 in Treg developmentR01AI191447 · NIAID · WASHINGTON UNIVERSITY · PI CHYI S HSIEH, Kenneth M Murphy · 2025 to 2026
$1.5MTranscriptional basis of embryonic macrophage developmentR21AI163421 · NIAID · WASHINGTON UNIVERSITY · PI MURPHY, KENNETH M · 2022 to 2023
$430kNCI NIH HHS P30 CA091842NCI NIH HHS P50 CA196510NCI NIH HHS R01 CA240983NCI NIH HHS R01 CA248919NHLBI NIH HHS 75N92020D00005NIAID NIH HHS 75N93022D00005NIAID NIH HHS R01 AI150297NIAID NIH HHS R01 AI162643NIAID NIH HHS R01 AI191447NIAID NIH HHS R21 AI163421NIDA NIH HHS 75N95020D00005NIH HHS 75N93023D00005NIH HHS 75N99020D00005
Abstract
Vaccines composed of mRNA and lipid nanoparticles (LNPs) activate B cells and T cells by inducing in vivo production of specific protein antigens. While B cells can be activated directly by antigens, T cell activation requires antigen processing and presentation by MHC molecules on specialized antigen-presenting cells (APCs). In response to viral infections, tumours, and protein- and cDNA-based vaccines, antigen presentation to CD8
Indexed as
CD8-Positive T-LymphocytesCross-PrimingmRNA VaccinesAnimalsAntigen PresentationCancer VaccinesDendritic CellsFemaleHistocompatibility Antigens Class IImmunologic MemoryInterferon Type ILipidsLiposomesLymphocyte ActivationMiceMice, Inbred C57BLCancer VaccinesHistocompatibility Antigens Class IInterferon Type ILipid NanoparticlesLipidsLiposomesmRNA Vaccines
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.